Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

ACE-031

£96.42£105.40

Buy ACE-031 1mg Peptide Vial

ACE-031 is a soluble form of the activin receptor type IIB (ActRIIB), functioning as a potent regulator of muscle growth by binding to myostatin and other negative regulators of muscle mass. It has been studied for its potential therapeutic applications, particularly in the treatment of muscular disorders such as Duchenne muscular dystrophy (DMD). The peptide is known to have the capacity to increase bone density and preserve muscle function, offering promising avenues for future research and development in muscle-related pathologies.

Buy 10 and get 10% Discount

479 in stock

Description

ACE-031 Peptide Vial 1mg New Zealand

This product is intended for research purposes only. To be used by trained professionals only.
New Zealand Research has shown ACE-031 peptide is a myostatin prevention healthy protein, it is generated to mimic an all-natural receptor in controlling muscular tissue mass, strength and function. ACE-031 functions as a myostatin blocker by binding myostatin [1]. Added proteins manage the role of myostatin. Myostatin is a vital, healthy protein, which in turn functions to avoid growth and also the development of muscle mass cells.

Myostatin usually limits muscular growth by stopping cell chemical signals and myogenesis. However, ACE-031 seems to bind to myostatin, which limits restrictive and increases muscle growth signals. ACE-031 has undergone many New Zealand clinical studies, focusing on treating children with muscular dystrophy from Duchenne or DMD. New Zealand Animal studies suggest the Belgian blue bull generates less myostatin than other breeds of cows. They also have an enhanced variety of muscle mass fibres, leading to lean, hyper-sculpted, ultra-muscular bodies.

In addition, reports say ACE-031 works by binding myostatin, which prevents it from binding to its very own receptors. Myostatin is the protein responsible for limiting the size and mass that muscle tissue can grow. As ACE 031 is binding to the myostatin protein, it prevents myostatin from taking effect on the muscle, allowing the muscle to continue to grow in size and mass without limitation. As a result, human studies showed increases in lean muscular tissue mass and muscle mass volume [2].

Furthermore, ACE 031 has beneficial effects on fat and bone biomarkers. With the multiple studies on myostatin inhibitors showing a promising capacity to treat muscle wastage diseases, ACE-031 is an appealing method for treating DMD and ALS [3].


References:

[1] https://www.clinicaltrialsarena.com/ projects/ ace031forthetreatmen/

[2] https://www.ncbi.nlm.nih.gov/ pubmed/27462804

[3] https://clinicaltrials.gov/ct2/ show/NCT01099761


ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our New Zealand Direct Peptides website: https://new-zealand.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.


BUY ACE-031 ONLINE today From New Zealand Direct Peptides

You may also like…